Theres even room for more lines. But the allure of the space is that when a company wins, its shareholders win big. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days later. Don't overlook another approach, especially if you're still sitting on a nice gain even after last week's major sell-off. From a near-term standpoint, there are two key risks. By the beginning of March, the stock was still trading at 45 cents as news of the coronavirus spreading in China prompted concerns about a U.S. pandemic. It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. At the time, Ocugen was left for dead. Maybe. One thing seems certain, however:Ocugens fate as an investment is closely tied to the ultimate outcome of Covaxin. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Instead, this appears destined to join the long list of failed biotech startups. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. But it does mean something. If they invent a miracle treatment for a condition, the money will find its way to the stock. From the outside looking inward, it looks like a marriage of two people who got together simply because nobody else would take them. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! The Motley Fool->. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Shares of Ocugen ( OCGN -3.10%) fell on Tuesday after an analyst sounded a note of caution to investors. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open. Click here to see what Matt has up his sleeve now. What should investors do now? Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. Keith Speights has no position in any of the stocks mentioned. These options will be cheaper than owning the stock itself. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. Emergency Use . You can be a growth investor, futures trader, deep-value investor, a day trader, options player, or a dividend aficionado. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. The equity has experienced a continual decline for years. Type a symbol or company name. The company initiated its Phase 3 trial of OCU300 back in July 2018. In that list, you can even include penny-stock trader. Keith Speights owns shares of Pfizer. The chances of anything more are small but the rewards could be huge. However, even from this limited vantage point, OCGN appears destined to fail. ET on Friday. Part of the proceeds will be used to support its partnership with Bharat. Copyright As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. Type a symbol or company name. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.. CFO Sanjay Subramanian said that there was "the potential for near-term revenue," depending on the EUA. It brings in no revenue. This decision isn't surprising, considering that Ocugen previously abandoned the pursuit of an EUA path for the vaccine in adults. The Ocugen deal is a way to salvage some limited value. The combined company has an agreement to sell the rights to NeoCart to privately held Medavate, leaving it reliant on Ocugens pipeline. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion 0.90% SPY 0.59% QQQ 0.60% TSLA 6.12% SI 60.35% CRM 11.51% RIVN 0.32% ARKK 0.96% RLY.X 56.44% PLUG 6.72% V 0.22% CDIO 13.87% RETA 5.92% More Advertisement 3rd Party Ad. If were playing that game then Im buying LEAP call options on Apple and Amazon in March. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. As of 1:37 p.m. EST, the biopharmaceutical company's stock price was down more than 15%.. The Ocugen 52-week high stock price is 4.03, which is 328.7% above the current share price. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. Investors need to understand the risk profile here. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. Copy and paste multiple symbols separated by spaces. Keith Speights for I am all for a good opportunity, but I dont know why some investors insist on penny stocks. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. But realizing value in practice usually is a difficult endeavor. All rights reserved. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Can you feel the ground moving beneath your feet? Ramakanth believes the broad immunity targeting different components of the virus could potentially provide better protection against emerging mutant viruses, such as the one currently circulating in the UK. With this in mind, in the Phase 1 study, COVAXIN has shown robust antibody responses against spike (S1) protein, receptor-binding domain (RBD) and the nucleocapsid (N) protein of SARS-CoV-2. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. If they have solid financials, but their trials continually fail, they will likely not succeed. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. Thats not a new problem: a previous Phase 1/2 study, according to the prospectus, was discontinued early due to slow enrollment. The company noted that additional trials may be required as well. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Plus500. In December, Ocugen stated that it had put together an advisory board of "leading academic and industry experts to evaluate the clinical and regulatory path to approval in the U.S. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. Ocugen. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. The short answer is: everything. To be sure, current cash isnt enough. Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. Do Not Sell My Personal Information (CA Residents Only). Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. Covaxin doesn't have an advantage in terms of dosing compared to these leading vaccines. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days. Historical daily share price chart and data for Ocugen since 2023 adjusted for splits. The potential synergies of such a union do not seem clear. The statistics support having long-term exposure to this asset class. All rights reserved. For now, though, what happens in India stays in India. After encouraging preliminary results, Ocugen began trying to sell 100 million doses of the vaccine in February. Investing is always a game of balancing risk and reward. MALVERN, Pa., May 29, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO International Convention, taking place June 4-7, 2018, in Boston. The stock had gained some traction after they announced the. With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell Amryt Pharma releases Q-2 how to setup copy trading labrador gold stock that show strong revenue growth as The first split for NKE took place on October 08, Below, we'll pit these two dominant consumer-discretionary giants against each other, with an eye toward long-term . Copyright 2023 InvestorPlace Media, LLC. Under the terms of the agreement, Ocugen is entitled to 45% of the profits from the commercialization of Covaxin in the U.S. and Canada. Start trading Options with Saxo today. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. There's a pretty good case to be made that other stocks offer even better prospects for returns with lower risk than Ocugen does. Honestly, OCGN stock is unlikely to survive. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. Ocugen estimates the drug could have as many as 63,000 potential patients. Investors who have owned stocks in the last year have generally experienced some big gains. See disclosure here. The Motley Fool has a disclosure policy. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. Copyright With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. Ocugens Big Run: One company that has been a home-run investment in the last year has been biotech stock Ocugen Inc (NASDAQ:OCGN). Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. Its certainly possible the deal will fall through, leaving Ocugen with just the $15.8 million in cash with which it closed the third quarter, according to its 10-Q. Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Copyright 2023 InvestorPlace Media, LLC. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Considering the conditions facing the company, I do not recommend Ocugen stock regardless of risk tolerances. Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen.
World's Strictest Parents Where Are They Now Joey,
Covid Portal Ri,
Racoons For Sale In Pa,
Articles O
ocugen stock crash 2018